New Authorized Generic Re-Pricing Rule Applied to Olmetec, Crestor AGs

March 6, 2018

Authorized generic (AG) versions of Daiichi Sankyo’s hypertension drug Olmetec (olmesartan) and AstraZeneca’s cholesterol fighter Crestor (rosuvastatin) will become the first AGs to face a new AG re-pricing rule to be introduced in the FY2018 drug price revision this April...read more